Results 81 to 90 of about 7,115 (194)

LC-MS method for determination of olmesartan in human plasma

, 2015
Olmesartan belongs to a class of drugs called angiotensin II receptor blockers (ARBs). It works by relaxing blood vessels so that blood can flow more easily and is used to treat high blood pressure (hypertension).
Edyta Piórkowska, Agnieszka Tycz, Piotr J. Rudzki, Jacek Musijowski, Katarzyna Buś - Kwaśnik   +4 more
core   +1 more source

Olmesartan-induced enteropathy treated with budesonide

, 2019
: Olmesartan, an angiotensin receptor blocker, is a widely spread antihypertensive drug. Seronegative vinous atrophy of the small intestine due to olmesartan use was first described in 2012.
Bogaert, J., De Maeyer, M., Van Hauthem, P., Kempenaers, S., Schoeters, P., Ramael, M.   +5 more
core   +1 more source

Method Validation for Simultaneous Quantification of Olmesartan and Hydrochlorothiazide in Human Plasma Using LC-MS/MS and Its Application Through Bioequivalence Study in Healthy Volunteers

Frontiers in Pharmacology, 2019
A new, simple, sensitive, selective, rapid, and high-throughput liquid chromatography-tandem mass spectrometry (LC-MS/MS) method has been developed and validated for simultaneous quantification of Olmesartan and hydrochlorothiazide in human plasma ...
Arvind Kumar, Arvind Kumar, Surya Prakash Dwivedi, Tulika Prasad   +3 more
doaj   +1 more source

Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies.

, 2013
The purpose of this study was to evaluate a fixed olmesartan/amlodipine combination on blood pressure control, lipid profile, insulin sensitivity, and some inflammatory markers compared with single-drug monotherapy.
Maffioli P., Carbone A, Cicero A, Fogari E, Querci F, Derosa G, D'Angelo A   +6 more
core   +1 more source

Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals

Кардиоваскулярная терапия и профилактика, 2011
Background. For patients with hypertension, effective 24-hour blood pressure (BP) control is vital to ensure protection against the early morning surge in BP and the associated increased risk of cardiovascular events.
Hans R. Brunner, Kikuo Arakawa
doaj   +1 more source

Place in therapy of olmesartan

, 2017
Place in therapy of olmesartanOlmesartan has been de-reimbursed in France since January 2017 following a negative evaluation of its benefit/risk profile compared with other sartans. However, olmesartan is one of the antihypertensive blockbusters in Italy
Antonio Addis, Francesco Trotta
core   +1 more source

Olmesartan/amlodipine: a review of its use in the management of hypertension

Vascular Health and Risk Management, 2011
R KreutzInstitute of Clinical Pharmacology and Toxicology, Charité, Universtitätsmedizin – Berlin, GermanyAbstract: Combination therapy is an effective strategy to increase antihypertensive efficacy in those patients with poor blood ...
Kreutz R
doaj  

Olmesartan‐induced enteropathy

, 2015
Olmesartan‐induced ...
S Wallace (13279542), Neel Heerasing (13087041), C Hair (13340214)   +2 more
core  

Severe Spruelike Enteropathy Associated With Olmesartan

, 2012
Objective: To report the response to discontinuation of olmesartan, an angiotensin II receptor antagonist commonly prescribed for treatment of hypertension, in patients with unexplained severe spruelike enteropathy.Patients and Methods: All 22 patients ...
Mangan, Thomas F.,, Wu, Tsung-Teh,, Kelly, Darlene G.,, Herman, Margot L.,, Ludvigsson, Jonas F.,, Murray, Joseph A.,, Rubio-Tapia, Alberto,   +6 more
core   +1 more source

Olmesartan, an AT1 Antagonist, Attenuates Oxidative Stress, Endoplasmic Reticulum Stress and Cardiac Inflammatory Mediators in Rats with Heart Failure Induced by Experimental Autoimmune Myocarditis

International Journal of Biological Sciences, 2011
Studies have demonstrated that angiotensin II has been involved in immune and inflammatory responses which might contribute to the pathogenesis of immune-mediated diseases.
Vijayakumar Sukumaran, Kenichi Watanabe, Punniyakoti T. Veeraveedu, Narasimman Gurusamy, Meilei Ma, Rajarajan A. Thandavarayan, Arun Prasath Lakshmanan, Ken'ichi Yamaguchi, Kenji Suzuki, Makoto Kodama
doaj